Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

468 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Next generation immune-checkpoints for cancer therapy.
Donini C, D'Ambrosio L, Grignani G, Aglietta M, Sangiolo D. Donini C, et al. Among authors: aglietta m. J Thorac Dis. 2018 May;10(Suppl 13):S1581-S1601. doi: 10.21037/jtd.2018.02.79. J Thorac Dis. 2018. PMID: 29951308 Free PMC article. Review.
Allogeneic nonmyeloablative hematopoietic cell transplantation in metastatic colon cancer: tumor-specific T cells directed to a tumor-associated antigen are generated in vivo during GVHD.
Carnevale-Schianca F, Cignetti A, Capaldi A, Vitaggio K, Vallario A, Ricchiardi A, Sperti E, Ferraris R, Gatti M, Grignani G, Rota-Scalabrini D, Geuna M, Fizzotti M, Sangiolo D, Sottile A, De Rosa G, Bucci AR, Lambertenghi-Deliliers G, Benedetti E, Nash R, Aglietta M. Carnevale-Schianca F, et al. Among authors: aglietta m. Blood. 2006 May 1;107(9):3795-803. doi: 10.1182/blood-2005-10-3945. Epub 2006 Jan 10. Blood. 2006. PMID: 16403911 Free article.
Positron-emission tomography in cancer therapy.
Aliberti S, Grignani G, Aglietta M. Aliberti S, et al. Among authors: aglietta m. N Engl J Med. 2006 May 4;354(18):1958-60; author reply 1958-60. N Engl J Med. 2006. PMID: 16673532 No abstract available.
Alloreactivity and anti-tumor activity segregate within two distinct subsets of cytokine-induced killer (CIK) cells: implications for their infusion across major HLA barriers.
Sangiolo D, Martinuzzi E, Todorovic M, Vitaggio K, Vallario A, Jordaney N, Carnevale-Schianca F, Capaldi A, Geuna M, Casorzo L, Nash RA, Aglietta M, Cignetti A. Sangiolo D, et al. Among authors: aglietta m. Int Immunol. 2008 Jul;20(7):841-8. doi: 10.1093/intimm/dxn042. Epub 2008 May 9. Int Immunol. 2008. PMID: 18469328
Sorafenib blocks tumour growth, angiogenesis and metastatic potential in preclinical models of osteosarcoma through a mechanism potentially involving the inhibition of ERK1/2, MCL-1 and ezrin pathways.
Pignochino Y, Grignani G, Cavalloni G, Motta M, Tapparo M, Bruno S, Bottos A, Gammaitoni L, Migliardi G, Camussi G, Alberghini M, Torchio B, Ferrari S, Bussolino F, Fagioli F, Picci P, Aglietta M. Pignochino Y, et al. Among authors: aglietta m. Mol Cancer. 2009 Dec 10;8:118. doi: 10.1186/1476-4598-8-118. Mol Cancer. 2009. PMID: 20003259 Free PMC article.
A phase 2 trial of imatinib mesylate in patients with recurrent nonresectable chondrosarcomas expressing platelet-derived growth factor receptor-α or -β: An Italian Sarcoma Group study.
Grignani G, Palmerini E, Stacchiotti S, Boglione A, Ferraresi V, Frustaci S, Comandone A, Casali PG, Ferrari S, Aglietta M. Grignani G, et al. Among authors: aglietta m. Cancer. 2011 Feb 15;117(4):826-31. doi: 10.1002/cncr.25632. Epub 2010 Oct 5. Cancer. 2011. PMID: 20925044 Free article. Clinical Trial.
468 results